Olumi_CV_4_2016

1
Curriculum Vitae
Date Prepared: April 18, 2016
Name: Aria F. Olumi, M.D.
Office Address:
Massachusetts General Hospital
55 Fruit Street
Yawkey Center, Suite 7E
Boston, MA 02114 United States
Home Address:
200 Brookline Street
Newton, MA 02459 United States
Work Phone: (617)643-0237
Work FAX: (617)643-4019
Work E-Mail: Olumi.Aria@mgh.harvard.edu
Place of Birth: London - England
Education
1987 B.A., (Cum laude) Chemistry University of California,
San Diego
1992 M.D. Medicine
University of Southern
California School of
Medicine
Postdoctoral Training
06/92-06/93 Intern Surgery Brigham & Women's
Hospital
07/93-06/94 Resident Surgery Brigham & Women's
Hospital
07/94-06/95 Resident Urologic Surgery Harvard Program in
Urology (Longwood
Area)
07/95-06/98 Research Fellow
Postdoc (Advisor: Thea
D. Tlsty, PhD.)
Molecular Medicine University of California,
San Francisco
07/98-06/00 Resident Urologic Surgery Harvard Program in
Urology (Longwood
Area)

2
Faculty Academic Appointments
2000-2003 Instructor Surgery/Urology Harvard Medical School
2003-2010 Assistant Professor Surgery/Urology Harvard Medical School
2010-2016 Associate Professor Surgery/Urology Harvard Medical School
2016-present Professor Surgery/Urology Harvard Medical School
Appointments at Hospitals/Affiliated Institutions
2000-2007 Staff Surgeon Surgery/Urology Beth Israel Deaconess
Medical Center
2007-present Staff Surgeon Urology Massachusetts General
Hospital
Major Administrative Leadership Responsibilities:
2000-2006 Director of Laparoscopy Program Beth Israel Medical Deaconess Center
2000-2007 Director of Post-graduate Training Beth Israel Medical Deaconess Center
2007- present Director of Urologic Research Massachusetts General Hospital
2010-present Co-director GU Oncology Clinical
Program
2010-2013 Director Urologic Oncology
Fellowship Program
2013-2015 Director Combined Harvard Urologic
Oncology Fellowship Program
Massachusetts General Hospital and
Brigham & Women’s Hospital
2014-present Urology Residency Program Director Massachusetts General Hospital
Committee Service
Local
2000-2004 Cancer Registry Beth Israel Medical Deaconess Center
2000-2004 Informational Systems Representative Beth Israel Medical Deaconess Center
2002-2007 Co-Chair: Prostate Cancer Tissue
Bank
Beth Israel Deaconess Medical Center
2005-2007 Co-Chair: GU Oncology Conference Beth Israel Deaconess Medical Center
2005-2007 Chair: GU/Harvard Monthly Data
Club
Beth Israel Deaconess Medical Center
2009 – present MGH Cancer Center Leadership
Committee
2012-present Resident Education Committee Massachusetts General Hospital
2014 Scientific Program Committee Society of Basic Urologic Research Fall
2014 Meeting
Professional Societies

3
1992-present Society of Basic Urologic Research
1994- present American Urological Association
1995- present American Association of Cancer Research
2013-present Research Council Executive Committee,
American Urological Association
2000-present Society of Urologic Oncology
2014-present Society of Urologic Oncology, Executive
Committee - Fellowship Programs
2015-2019 Chair of Research Council, American Urological
Association
Honorary Societies:
2012-present Society of University Surgeons
Grant Review Activities
2002-2008 Cell Biology 2
Ad hoc Member
Department of Defense – Prostate
Cancer Program
2007 Clinical/Translational
Ad hoc Member
Department of Defense – Prostate
Cancer Program
2009-2012 Grant Review Committee
Permanent Member
American Urological Assc.
Foundation Grants
2011 Grant Review Committee
Ad hoc Member
Prostate Cancer Charity,
United Kingdom
Ad hoc Member
Diabetes Research Wellness
Foundation, United Kingdom
Ad Hoc Member
American Urological Assc.,
Rising Star in Urology Research
Ad Hoc Member
NIH/Diabetes Complications
Consortium
Ad hoc Member
NIH/ZRG1 DKUS-G(90) review
committee
6/2015 Grant Review Committee
Ad hoc Member
committee
Chairperson
committee

4
Chairperson
American Urological Assc.
Research Scholar Grant
Editorial Activities
Ad hoc Reviewer:
American Journal of Pathology
Annals of Surgical Oncology
Apoptosis
British Journal of Urology
Cancer Letters
Cancer Research
Carcinogenesis
Cell Death & Differentiation
Clinical Cancer Research
Diabetes
European Urology
International Journal of Cancer
JNCI
Journal of Clinical Oncology
Journal of Urology
Medicine
Molecular Cancer Therapeutics
Molecular Carcinogenesis
Molecular Pharmacology
New England Journal of Medicine
Nucleic Acid Research
Oncogene
Pharmacology & Therapeutics
PLoS One
Proceedings of National Academy of Sciences
Prostate
Prostate Cancer and Prostatic Diseases, Nature
Surgery
Urologic Oncology
Urology
2005- present Editorial Board Member Journal of Urology
2007-2009 Assistant Editor Journal of Urology
2013-present Associate Section Editor Journal of Urology, Investigative
Urology Section
Honors and Prizes
1989 & 1990 Baxter Foundation
Research Award
Medicine
Medical Student
Research Award
1991 Medical Student Research
Award
Medical Student
Research Award

5
Medicine
1997 Young Investigator's
Travel Award
Society of Basic Urologic
Research
Research
Accomplishment
1998 Young Investigator's
Travel Award
American Assc. Of
Cancer Research
Research
Accomplishment
1999 & 2000 Countway Library
Urology Resident
Research Award, First
Place
Harvard Program in
Urology
Research
Accomplishment
2005 Young Investigator
Award
Research
Research
accomplishments
before age of 40
2/09 -2/11 Staff Physician Physician Leadership
Development Course
Massachusetts
General Hospital
2015-2019 Chair, Research Council American Urological
Assc.
Selected with the
mission to guide and
implement the
research efforts for
the largest
international urologic
society (with 0.2 FTE
salary support)
Report of Funded and Unfunded Projects
Past – Funded Projects
Year(s) funded Role on Project Funding Source Total direct cost
1997-1998 P.I. CaPCURE $100,000
Role of primary and metastatic adenocarcinoma of prostate by the associated
stroma
Purpose: to evaluate the role of normal and carcinoma-associated fibroblasts in
promoting prostate epithelial tumorigenesis.
2002-2004 P.I. for Developmental
Project
NCI-Prostate Cancer
SPORE – DFCI/Harvard
$100,000
The Role of Anti-Apoptotic Factors in Evasion of Prostate Tumors from
TRAIL-Induced Apoptosis
Purpose: to determine whether c-FLIP, an anti-apoptotic molecule regulates
sensitivity to pro-apoptotic agents
2003-2009 P.I. NIDDK -- K08
DK064062
$650,000

6
Role of Stromal-Epithelial Interactions in BPH
Description of major goals: to evaluate the paracrine signaling mechanism
between prostate stromal & epithelial cells. We discovered several stromal
paracrine factors that promote prostate epithelial cell proliferation.
2004-2005 P.I. Howard Hughes
Medical
Institute/Harvard
Medical School
Grant #: 53000234-0006
$100,000
Role of c-FLIP(L) in modulating apoptosis in prostate cancer
Purpose: To evaluate the transcriptional regulation of c-FLIP, an anti-apoptotic
molecule, in prostate cancer pro-apoptotic therapies.
2004-2009 P.I. Department of Defense
W81XWH-05-1-0080
$225,000
Role of c-FLIP(L) in apoptosis
Purpose: to evaluate molecular mechanisms to overcome resistant prostate
cancer cells which are treated by pro-apoptotic therapies like TRAIL. We
identified novel molecular interactions between c-FLIP and c-Fos which are
integral in regulating TRAIL-induced apoptosis.
2007-2008 P.I. for Developmental
Project
NCI-Renal Cancer
SPORE – DFCI/Harvard
$30,000
Orthotopic Renal Cancer Model for HIF regulated Renal Cell Carcinoma
Purpose: to develop an orthotopic model for therapies related to renal cell
cancer. In the orthotopic model, we assessed tumorigenicity and response to
therapy of renal cancer cell lines with different VHL mutations which were
known to differentially regulate the hypoxia inducible factor molecule.
2008-2010 P.I. Bertucci Prostate Cancer
Foundation at MGH
$134,000
Finasteride - Promoter or Repressor of Prostate Cancer Cells
Purpose: Finasteride is a commonly used therapy for patients with benign
prostatic hyperplasia, and more recently, it has also been promoted as a
chemopreventive agent against prostate cancer. We have found that Finasteride
may have a paradoxical effect and promote tumor progression in some settings.
2009-2011 P.I. New York Academy of
Medicine/Edwin Beer
Fellowship
$80,000
c-FLIP and c-Fos Regulate Sensitivity & Resistance to TRAIL-induced
Apoptosis in Prostate Cancer Cells
Purpose: to determine the role of c-Fos and c-FLIP in TRAIL-induced
apoptosis. To define the molecular mechanism that c-Fos regulates c-FLIP, in
order to design strategies to overcome resistant prostate cancers treated by pro-
apoptotic therapies.
2009-2010 P.I. NIH/NIDDK – Animal
Models of Diabetic
$60,000

7
Complications Pilot &
Feasibility Project,
09MCG72
2011-2013 P.I. American Urological
Association and Pfizer
$75,000
Inflammatory Mediators and Bladder Dysfunction in Type 2 Diabetes
Purpose: Urologic complications associated with diabetes are very common,
however, the molecular mechanisms that affect bladder dysfunction in patients
with diabetes is poorly understood. In this project we evaluate and define the
role of inflammatory mediators in bladder dysfunction that is associated with
type 2 diabetes.
2012-2013 Co-PI (PI: Wu, CL) Myriad Genetics $200,000
Assessment of Polaris Molecular Marker for outcome and survival of
surgically treated prostate cancer patients with radical prostatectomy.
Purpose: this project assess the outcome of surgically treated prostate cancer
patients with biomarkers developed by Myriad Genetics company
Current – Funded Projects
2011-2016 P.I. NIH/NIDDK
R01 DK087952-01
$1,250,000
Reduced levels of 5-α reductase 2 in adult prostate tissue: Implications for BPH
therapy
Purpose: 25-30% of human prostate tissues do not express the 5- α reductase 2
enzyme. We hypothesize that men who do not express 5-α reductase 2 in the
prostate are likely to be resistant to Finasteride for treatment of BPH. The
proposal is designed to investigate the mechanisms of resistance to 5-α
reductase 2 inhibitors.
2013-2014 P.I. NIH/NIDDK
3 U24 DK076169-08S4
Diabetic Complications
Consortium
$100,000
The Effect of High-Fat Diet on Diabetic Bladder Dysfunction in Type 2
Diabetes
Purpose: Although diabetic bladder dysfunction affects up to 80% of patients
with DM2, its underlying pathophysiology is poorly understood. Using a
genetically modified type 2 diabetic animal model, we have identified specific
molecular pathways important for diabetic bladder dysfunction. Here, we
examine whether high fat diet, in combination with DM2 will exacerbate the
secondary complication of DM2 by worsening lower urinary tract symptoms.
Report of Local Teaching and Training
Teaching of Students in Courses
2000-2007 Urology Lecture Series Beth Israel Deaconess Med Ctr
20 hours per year
3rd
year Harvard Medical Students on surgery clerkship;
Role: teacher and organizer of the lecture series

8
2008 – present 2nd
year Harvard Medical Students; Renal
Pathophysiology-- course #: IN757.REN– Urology
Session Role: lecturer & Session Director
o Developed Urology curriculum for 2nd
year HMS
students that is presented in the Renal
Pathophysiology section
Harvard Medical School
10 hours per year
2012-present 2nd
year Harvard Science Technology Renal Curriculum
– Bladder function/dysfunction and evaluations by
urodynamics – course #: HT110
Role: lecturer
3 hours per year
2011-present Organized annual information session and laparoscopy
skills lab for all HMS students to introduce them to the
field of urology. Gathered faculty members from Beth
Israel Deaconess, Brighma & Women’s, Children’s and
Mass General Hospitals to showcase different
subspecialties of urology.
3 hours per year
Formal Teaching of Residents, Clinical Fellows and Research Fellows
2000-2006 Urology Resident Weekly Conference Two hours per week
PGY-1 to PGY-6 residents;
Role: teacher/moderator
2013-present Urologic Oncology Didactic Session – Urologic Oncology
fellows and faculty
Two hours per month
Clinical Supervisory and Training Responsibilities
2000 – 2004 Urologic laparoscopic animal
training. Organized a series of
animal labs to train faculty &
residents in urologic laparoscopic
techniques
Beth Israel Deaconess
Medical Center
Two 6-hr sessions per
year
Laboratory and Other Research Supervisory and Training Responsibilities
2000 – 2006 Supervision of post-doctoral
clinical/basic science research
Beth Israel Deaconess
Medical Center
Weekly mentorship of
research fellows – 4
hours per week
2007- Supervision of post-doctoral
clinical/basic science research.
Currently, oversee 4 postdocs
Massachusetts General
Hospital
Weekly mentorship of
research fellows – 4
hours per week
Formally Supervised Trainees
9/2000 to 4/2004 Ignacio San Francisco, M.D. Urology faculty: University of

9
Chile – Catholic Hospital
o Published 7 clinical and basic science papers.
o One publication cited 192 times as of 8/2015: “Extended prostate needle biopsy
improves concordance of Gleason grading between prostate needle biopsy and
radical prostatectomy”, JUrol, 169, 136-140, 2003
10/2001 to 2/2003 Jean Ung Ou, M.D. Urology private practice,
Illinois
o Published one paper about prostate needle biopsy strategies.
9/2002 to 9/2007 Xiaoping Zhang, MD, PhD Professor & Chairman of
Urology, Huazhong University
of Science & Technology,
Union Hospital, Wuhan, China
o Published 11 manuscripts with publications in Molecular Cell, Cancer Research
and Clinical Cancer Research and authored several review articles.
o One publication cited 121 times as of 2/2014: “Persistent c-FLIP (L) expression
is necessary and sufficient to maintain resistance to tumor necrosis factor-related
apoptosis-inducing ligand–mediated apoptosis in prostate cancer”, Cancer
Research, 64: 7086-7091, 2004
3/2005 to 7/2005 &
7/2012-6/2014
Glen Barrisford, M.D. Attending urologist at US
Navy, Bethesda, MD then
joined Urologic Oncology
Fellowship at Mass General.
Director of Urologic Oncology
at Kaiser Permanente, Santa
Rosa, CA
o Developed in-vivo models of TRAIL induced apoptosis in Renal Cell Carcinoma
and co-authored in one manuscript.
10/2004 to 12/2006 Liang Zhang, MD, PhD Radiology Resident in training
o Evaluated mechanisms of resistance in renal cancer apoptotic therapy. Published
four manuscripts.
10/2004 to 12/2006 Xu Huang, PhD Scientist at Department of
Public Health, Boston
o Published three manuscripts.
11/2004 to 11/2007 Wenhua Li, PhD Professor of Molecular/Cellular
Biology, Wuhan University,
China
o Published four manuscripts and was recruited to Wuhan University as a basic
science faculty member.
10/2007 to present Rongbin Ge, MD, PhD Continuing as Postdoc in my
lab, applying for pathology
residency
o Has defined novel molecular pathways that regulate resistance to pro-apoptotic

10
therapies.
2/2008 to present Yinong Niu, M.D., PhD. Urology faculty – Beijing
Hospital, China
o Examined the molecular mechanisms of resistance to Finasteride in patients with
benign prostatic hyperplasia.
9/2008 to present Zongwei Wang, M.D., PhD. Postdoc in my lab, Promoted to
rank of Instructor at Harvard
Medical School
o Has been evaluating the molecular mechanisms of bladder dysfunction in type 2
diabetes
o Published paper in journal Diabetes delineating the molecular mechanism of
diabetic bladder dysfunction
10/2010 to 10/2012 Johannes Gregory Wirth, M.D. Urology Faculty Member –
University Hospitals Geneva
o Examined the metabolic effect of metformin on prostate cancer cell survival.
o Published 3 clinical and basic science manuscripts
6/2012 to 6/2013 Crystal Dover, M.D. Duke University –
Female/Reconstructive Urology
Fellowship; Practicing
Urologist
o Examined for molecular markers for bladder dysfunction in patients with type 2
diabetes
7/2011 to
6/2014
Mark Preston, M.D. Urologic Oncology Fellow –
Mass General Hospital
Assistant Professor of Urology at
Harvard Medical School and
Brigham & Women’s Hospital
o Obtained young investigator award grant from American Urological Assc. to
evaluate role of 5-alpha reductase inhibitors in prostate cancer.
o Manuscript accepted for publication in JAMA Int Med
9/2012 to
3/2013
Evgeniy Kreydin, M.D. Fellow in Female Urology at
UCLA
o Examined molecular pathways responsible for diabetic bladder dysfunction
9/2012 to
3/2013
J. Scott Gabrielsen , M.D., Ph.D. Urology Resident
o Examined molecular pathways responsible for diabetic bladder dysfunction
9/2013 to
3/2014
Seth Bechis, M.D., M.S. Urology Resident
o Evaluated methylation of 5-alpha reductase 2 gene in human prostate tissue.

11
o Published a first-author original paper, co-author of a second original paper, and
first author of a review paper. In addition, has been awarded first place resident
essay contest at New England annual AUA meeting and selected as 1 of 4 best
research presentations at annual AUA meeting with more than 16,000
participants.
6/2011 to
present
Rena Xu, M.D., M.B.A. Urology Resident
o Published one manuscript about management of lung nodules in patients with
renal cancer.
o Developed a mobile device app for improving enrollment in clinical trial as part
of Harvard Business School project.
Local Invited Presentations
No presentations below were sponsored by outside entities
2004-2014 Surgical Management of Localized & Metastatic
Renal Cell Cancer
International Meeting for
Harvard Urologic Cancer Course
Departments of Surgery, Medicine, Radiation
Oncology, Harvard Medical School
Source of compensation: none
Report of Regional, National and International Invited Teaching and
Presentations
Regional Invited Presentations
2004, 2011,
2014
New England American Urologic Association
Annual Meeting
Basic Science Session
Invited scientific moderator for basic science
session
National Invited Presentations
2010 Cooperative Opportunities for Treatment of Renal
Cell Carcinoma
Visiting Professor, University of
Arkansas
2013 Inflammatory Mediators Associated with Bladder
Dysfunction in Type 2 Diabetes
Invited Speaker and Panel
Member,
Society for Urodynamics, Female
Pelvic Medicine and Urogenital
Reconstruction (SUFU), Las
Vegas, NV
2013 Dynamic expression of 5-alpha reductase in human
prostate tissue
Invited Speaker: University of
Southern California School of
Medicine, Los Angeles, CA

12
2014 Urologic Complications of Diabetes Invited Moderator: Combined
Society of Urologic Oncology &
Research Annual Meeting,
Orlando, FL
2014 Inflammatory Mediators and Diabetic Cystopathy Invited Speaker: Combined
Society of Urologic Oncology &
Research Annual Meeting,
Orlando, FL
2014 Omics in Urologic Research– New Frontiers
Driving Precision Medicine
Invited Moderator: Molecular
markers and targets for Urologic
diseases; Society of Basic
Urologic Research Annual
Meeting, Dallas, TX
2015 Variable Expression of 5-alpha reductase 2 -
Implications for Personalized Therapy for Prostatic
Diseases
Visiting Lecturer: Yale School of
Medicine, Urology Dept. Grand
Rounds
2015 Early Career Investigator Workshop – American
Urological Association
Invited faculty/mentor & lecturer
for young investigators,
Linthicum, MD
2015 Basic Science Research Presentations Invited Moderator: New England
& Mid-Atlantic American
Urological Assc. Meeting,
Nassau, Bahamas
2015 Personalized Therapy for Management of Benign
Prostatic Hyperplasia
Invited Speaker: American
Society of Men’s Health Annual
Meeting, Washington, DC
International Invited Presentations
2009 Surgical Management of Metastatic Renal Cell
Cancer
Invited Lecture
Department of Urology, Union Hospital, Huazhong
University of Science & Technology, Wuhan, China
Source of compensation: Union
Hospital, Wuhan, China
Cancer
Invited Lecture
Departments of Urology, Chao-Yang Hospital,
Capital Medical University
Source of compensation: Chao-
Yang Hospital
Cancer
Invited Lecturer
Departments of Urology, Beijing University, Source of compensation: none

13
2014 Variable Expression of 5-alpha Reductase 2:
Implications for Management of BPH and Prostate
Cancer
Invited Lecture
Departments of Urology, Pontificia Universidad
Catolica de Chile, Santiago
2014 Metformin as an anti-cancer agent against prostate
cancer
Invited Lecture
Departments of Urology, Pontificia Universidad
Catolica de Chile, Santiago
2015 American Urological Association faculty member
Sociedad Argentina de Urologia Annual Meeting,
Buenos Aires, Argentina
Invited Lecturer
2016 Designing a Research Project & Writing a
Manuscript: Increasing your Chance of Success
New York Section of American Urological
Association
Invited Lecturer
Source of compensation: NYS-
AUA
2016 Chief Judge – 66th
Annual Ferdinand C. Valentine
Resident Essay Contest at New York Section of
American Urological Association
Invited Judge
Source of compensation: NYS-
AUA
2016 New Initiatives for American Urological
Association Office of Research
Society of Urology Chairperson & Program
Directors
Invited Lecturer
2016 Urologic Oncology Scientific Session – Moderator
and Planning Committee
American Urological Association Annual Meeting,
San Diego, CA
Invited Organizer and Lecturer
2016 Plenary speaker: Highlights – Urologic Oncology
Scientific Session
San Diego, CA
Invited Lecturer
2016 Diabesity - Obesity and Age Promote Epigenetic
Suppression of Prostatic 5-alpha Reductase 2 -
Opportunities for Personalized Care in BPH
San Diego, CA
Invited Lecturer

14
Report of Clinical Activities and Innovations
Current Licensure and Certification
1992-present Massachusetts Board of Registration in Medicine
1993 National Board of Medical Examiners
1994-2000 Medical Board of California
2002-present American Board of Urology
Practice Activities
2000 to 2007 Urology/Urologic
Oncology Clinic
Outpatient Clinic Urology Clinic,
Shapiro Building,
BIDMC
12 hours per week
2000 to 2007 Urology/ Urologic
Oncology
Endoscopic Surgery
Operating Room BIDMC Operating
Room
4 hours per week
2000 to 2007 Urologic Oncology
Open procedures
Operating Room BIDMC Operating
Room
8 hours per week
2007 to present Genitourinary
Oncology
Multidisciplinary
Clinic
Outpatient Clinic GU Oncology
Clinic, Yawkey
7E, MGH
4 hours per week
2007 to present Urologic Oncology
Practice
Outpatient Clinic Yawkey 7E, MGH 8 hours per week
2007 to present Urologic Procedure
Clinic
Outpatient Clinic Wang 5, MGH 4 hours per week
Endoscopic Surgery
Operating Room MGH Operating
Room
4 hours per week
Open, Robotic and
Laparoscopic
procedures
Operating Room MGH Operating
Room
8 hours per week

15
Report of Scholarship
Publications
• Peer Reviewed Publications
Research investigations
1. Rideout WM 3d, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous
mutagen in the human LDL receptor and p53 genes. Science. 1990;249:1288-90.
2. Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA. Allelic loss of
chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the
bladder. Cancer Research. 1990;50:7081-3.
3. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH 3d, Gonzalez-Zulueta M, Nichols PW,
Skinner DG, Jones PA. Role of chromosome 9 in human bladder cancer. Cancer Research.
1993;53:4066-70.
4. Olumi AF, Dazin P, Tlsty TD. A novel coculture technique demonstrates that normal human
prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death.
Cancer Research. 1998;58:4525-30.
5. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM,
Carroll PR. Locally recurrent prostate tumors following either radiation therapy or radical
prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. Journal
of Urology. 1998;159:1437-43.
6. Olumi AF*, Grossfeld GD*, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (*contributed
equally). Carcinoma-associated fibroblasts direct tumor progression of initiated human
prostatic epithelium. Cancer Research. 1999;59:5002-11.
7. Olumi AF, Garnick MB, Renshaw AA, Benson CA, Richie JP. Leydig cell hyperplasia
mimicking testicular neoplasm. Urology. 1996;48:647-9.
8. Olumi AF, Richie JP, D’Amico AV. Calculated volume of prostate cancer identifies patients
with clinical stage T1c disease at high risk of biochemical recurrence after radical
prostatectomy: a preliminary study. Urology. 2000;56:273-7.
9. Olumi AF, Weidner N, Presti JJr. p53 Immunoreactivity Correlates with Ki-67 and Bcl-2
Expression in Renal Cell Carcinoma. Urologic Oncology. 2001;6:63-7.
10. San Francisco IF, Olumi AF, Kao J, Rosen S, DeWolf WC. Clinical management of prostatic
intraepithelial neoplasia as diagnosed by extended needle biopsies. British Journal of Urology.
2003;91:350.
11. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF. Extended prostate needle
biopsy improves concordance of Gleason grading between prostate needle biopsy and radical
prostatectomy. Journal of Urology. 2003;169:136-40.
12. San Francisco IF, Olumi AF, Yoon, JH, Regan, MM, DeWolf WC. Preoperative serum acid
phosphatase and alkaline phosphatase are not predictors of pathological stage and PSA failure
after radical prostatectomy. British Journal of Urology. 2003;92:924-8.
13. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. The relationship of prostate
gland volume to extended needle biopsy on prostate cancer detection. Journal of Urology.
2003;169:130-5.
14. San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. Expression of Transforming Growth
Factor-Beta 1 and growth in soft agar differentiates between prostate carcinoma-associated

16
fibroblasts from normal prostate fibroblasts in-vitro. International Journal of Cancer.
2004;112:213-18.
15. San Francisco IF, Regan, MM, DeWolf WC, Olumi AF. Outcome of patients after radical
retropubic prostatectomy: a comparison of prostate cancer diagnosed using extended needle
biopsy technique versus non-extended needle biopsy technique. UroOncology. 2004;4(2):85-
90.
16. San Francisco IF, Regan, MM, Olumi AF, DeWolf WC. Percent of positive cores for cancer is
a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate
specific antigen. Journal of Urology. 2004;171:1492-9.
17. Zhang X, Jin T, Yang H, DeWolf WC, Jin T, Khosravi-Far R, Olumi AF. Persistent c-
FLIP(L) Expression Is Necessary and Sufficient to Regulate Sensitivity to TRAIL-mediated
Apoptosis in Prostate Cancer. Cancer Research. 2004;64(19):7086-91.
18. San Francisco IF, Regan, MM, DeWolf WC, Olumi AF. Low age-adjusted free-testosterone is
associated with poorly differentiated prostate cancer. Journal of Urology. 2006;175(4):1341-
5;discussion 1345-6.
19. Zhang X, Zhang L, Yang H, Huang, X, Otu H, Liberman T, DeWolf WC, Khosravi-Far R,
Olumi AF. c-Fos as a pro-apoptotic agent in TRAIL-induced apoptosis in prostate cancer
cells. Cancer Research. 2007;67:9425-34.
20. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG
Jr. HIF linked to differential kidney cancer risk seen with type 2a and type 2b VHL mutations.
Molecular Cellular Biology. 2007;27:5381-92.
21. Zhang L, Zhang X, Barrisford G, Olumi AF. Lexatumumab (TRAIL-Receptor 2 mAb)
Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell
Carcinoma in a Mouse Orthotopic Model. Cancer Letters. 2007;251(1):146-157.
22. Zhang X, Li W, Olumi AF. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor
necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Clinical Cancer Research. 2007;13:7181-90.
23. Li W, Zhang X, Olumi AF. MG-132 Sensitizes TRAIL-resistant Prostate Cancer Cells by
Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L). Cancer Research.
2007;67(5):2247-55.
24. Yang H, Minamishima YA, Yan Q, Schlisio S, Zhang X, Zhang L, Kim WY, Olumi AF,
Kaelin WG Jr. Novel adapter role for pVHL: Promoting inhibitory phosphorylation of the NF-
kB agonist Card9 by CK2. Molecular Cell. 2007;28:15-27.
25. Li W, Wu CH, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of
prostate epithelial cells. American Journal of Pathology. 2007;171:1189-98.
26. Huang X, Zhang X, Farahvash B, Olumi AF. Novel targeted pro-apoptotic agents for
treatment of prostate cancer. Journal of Urology. 2007;178:1846-54.
27. Halperin TJ, Slavin SA, Olumi AF, Borud LJ. Surgical management of scrotal lymphedema
using local flaps. Annals of Plastic Surgery. 2007;59:67-79; discussion 72.
28. Zhang X, Li W, Olumi AF. Overcoming Resistance to TRAIL-Induced Apoptosis in Prostate
Cancer by Regulation of c-FLIP. Methods Enzymol. 2008;446:333-49.

17
29. Pedrosa I, Sun MR, Spencer M, Genega EM, Olumi AF, Dewolf WC, Rofsky NM. MR
imaging of renal masses: correlation with findings at surgery and pathologic analysis.
Radiographics. 2008;28(4):985-1003.
30. Olumi AF, DeWolf WC. The Hybrid of Basic Science and Clinical Training for the Urologic
Oncologist: Necessity or Waste? Urologic Oncology. 2009;27:205-7.
31. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, Yeh IT, Troyer DA,
Olumi AF, Kumar AP. Involvement of FLIP in 2-Methoxyestradiol-Induced Tumor
Regression in Transgenic Adenocarcinoma of Mouse Prostate Model. Clinical Cancer
Research. 2009;15(5):1601-11.
32. Zhang X*, Huang X*, Olumi AF (*contributed equally). Repression of NF-kB and Activation
of AP-1 Enhance Apoptosis in Prostate Cancer Cells. International Journal of Cancer.
2009;124(8):1980-9.
33. Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10: a novel NF-κB-dependent anti-
apoptotic protein regulates TRAIL-induced apoptosis. Cell Death and Differentiation. 2011;
18(7):1184-95.
34. Psutka SP, Feldman A, Rodin D, Olumi AF, Wu CL, McDougal WS. Men with Organ-
Confined Prostate Cancer and Positive Surgical Margins develop Biochemical Failure at a
Similar Rate to Men with Extracapsular Extension. Urology, 2011;78(1):121-5.
35. Niu N, Hu L, Diaz C, Ge R, Wang Z, Wu CL, Olumi AF. Reduced Levels of 5-α Reductase 2
in Adult Prostate Tissue and Implications for BPH Therapy. Prostate, 2011;71(12):1317-24
36. Wang Z, Cheng Z, Cristofaro V, Li J, Xiao X, Gomez P, Ge R, Gong E, Strle K, Sullivan MP,
Adam RM, White MF, Olumi AF. Inhibition of TNF-α improves the bladder dysfunction that
is associated with type 2 diabetes. Diabetes, 2012; 61(8):2134-45.
37. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A,
Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. Journal of
Clinical Oncology, 2012; 30(25):3071-6.
38. Dong F, Wang C, Farris AB, Wu S, Lee H, Olumi AF, McDougal WS, Young RH, Wu CL.
Impact on the clinical outcome of prostate cancer by the 2005 international society of
urological pathology modified Gleason grading system. American Journal of Surgical
Pathology. 2012; 36(6):838-43.
39. Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL. A
close surgical margin after radical prostatectomy is an independent predictor of recurrence.
Journal of Urology; 2012;188(1):91-7.
40. Gershman B, Dahl DM, Olumi AF, Young RH, Scott McDougal W, Wu CL. Smaller prostate
gland size and older age predict Gleason score upgrading. Urologic Oncology.
2013;31(7):1033-7.
41. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell
WK, Olumi AF, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated
reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to
glutamine deprivation; Cell Metabolism. 2013 Mar 5;17(3):372-85.
42. Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M,
Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN,
Olumi AF, Vander Heiden MG, Stephanopoulos G. Metformin decreases glucose oxidation

18
and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
Cancer Research. 2013;73(14):4429-38.
43. Aizer AA, Paly JJ, Zietman A, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A,
Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D’Amico AV, Efstathiou JA. Models of
Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer. Journal of National
Comprehensive Cancer Network. 2013; 11:1364-72.
44. Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q,
Olumi AF, Zhang X. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during
malignant transformation. Molecular Cancer Research. 2014;12:217-27.
45. Rodríguez R, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF. Primary
Spermatic Cord Tumors: Disease Characteristics, Prognostic Factors and Treatment
Outcomes. Urologic Oncology. 2014; 32:52.e19-25.
46. Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson
MD. Prognostic Significance of Indeterminate Lung Nodules in Renal Cell Carcinoma.
Urologic Oncology. 2014; 32:355-61.
47. Preston MA, Wilson K, Markt SC, Ge R, Morash C, Stampfer MJ, Loda MF, Giovannucci E,
Mucci LA, Olumi AF. 5α-reductase Inhibitors and Risk of High-grade or Lethal Prostate
Cancer. JAMA Internal Medicine, 2014;174:1301-7.
48. Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS. Clinical features of
leiomyosarcoma of the urinary bladder: Analysis of 183 cases. Urologic Oncology. 2014;
32:958-65
49. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO,
Sørensen HT. Metformin Use and Prostate Cancer Risk. European Urology. 2014; 66:1012-2.
50. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized Medicine for Management of Benign
Prostatic Hyperplasia, Journal of Urology. 2014; 192:16-23.
51. Ge, R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, Wu CL, Tabatabaei S, Olumi AF.
DNA Methyl Transferase 1 Reduces Expression of 5-alpha Reductase 2 in the Aging Adult
Prostate, American Journal of Pathology. 2015;185:870-82
52. Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong WD, Olumi A, Young RH, Wu CL.
Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma.
Hum Pathol. 2015; 46(6):820-6.
53. Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP. Activation of AKR1C1/ERβ induces
apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic
opportunity. Oncotarget. 2015; 6(13):11600-13.
54. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. Age
and Obesity Promote Methylation and Suppression of 5-Alpha Reductase 2--Implications for
Personalized Therapy in Benign Prostatic Hyperplasia. Journal of Urology, 2015; 194:1031-7.
55. Ge R, Wang Z, Wu S, Zhuo Y, Otsetov AG, Cai C, Zhong W, Wu CL, Olumi AF. Metformin
represses cancer cells via alternate pathways in N-Cadherin Expressing vs. N-Cadherin
deficient cells. Oncotarget. 2015; 6:28973-87.

19
• Peer Reviewed Publications
Other peer-reviewed publications (meta-analysis, meeting proceedings with full manuscript,
case reports etc.)
1. Olumi AF. A critical use of p53 as a marker for management of bladder cancer. Urologic
Clinics of North America. 2000;27:75-82.
2. Olumi AF. Self-retraction clamp for dissection of the posterior prostatic fossa during radical
retropubic prostatectomy. Scientific World Journal. 2004;4 (Suppl 1):260-2.
3. Kuten A, Olumi, AF, Goldsmith J, Monahan-Earley, RA, Dvorak AM, Genega EM.
Pathologic quiz case. A symptomatic renal tumor. Juxtaglomerular cell tumor. Archives of
Pathology Lab Medicine. 2004;128(9):e112-4.
4. Huang WY, Olumi AF, Rosen S. Urothelial mucosal malformation: a rare cause for
ureteropelvic junction obstruction. Pediatr Dev Pathol. 2006;9(1):72-4.
5. Adey GS, Genega EM, Pedrosa I, Olumi AF. Upper urinary tract carcinoma: transitional or
renal cell? Issues in Urology. 2006;18:234-8.
6. Wang Z, Olumi AF, Diabetes, Growth Hormone-Insulin-like Growth Factor Pathways and
Association to Benign Prostatic Hyperplasia. Differentiation. 2011; 82(4-5):261-71
7. Gershman B, Olumi AF, Precursors to Genitourinary Malignancies: A Clinical Approach,
AUA Update Series, 2012.
8. Rodríguez D, Olumi AF. Management of spermatic cord tumors: a rare urologic malignancy.
Therapeutic Advances in Urology. 2012 Dec;4(6):325-34.
9. JS Gabrielsen, Olumi AF. Scrotal & Testicular Lesions. In: Kiefer MM, Chong CR, eds.
Pocket Primary Care: A Massachusetts General Hospital Handbook. Philadelphia: Lippincott
Williams & Wilkins; 2014.
• Non-peer reviewed scientific or medical publications
(Reviews, chapters, monographs and editorials, Books/Textbooks for the medical or scientific
community, Letters to the Editor)
1. Olumi AF, Skinner EC, Tsai YC, Jones PA. Molecular analysis of human bladder cancer.
Seminars in Urology. 1990;8:270-7.
2. Rideout WM3rd, Coetzee GA, Olumi AF, Spruck CH, Jones PA. 5-Methylcytosine as an
endogenous mutagen in the p53 tumor suppressor gene. Princess Takamatsu Symposium.
1991;22:207-19.
3. Olumi AF, Richie JR. Surgical Treatment of Invasive Bladder Cancer In: Syrigos KN and
Skinner DG, editors. Bladder cancer: biology, diagnosis and management. Oxford Univ. Press.
1999.
4. Olumi AF. Book Review: Prostate Cancer: Biology, Genetics, and the New Therapeutics.
New England Journal of Medicine. Edited by Leland W.K. Chung, William B. Isaacs, and
Jonathan W. Simons. 2002:1677-8.
5. Singh, D, Olumi AF. Evaluation of Hematuria In: Furie B, Cassileth P, Atkins MB, and
Mayer R, editors. Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment.
Churchill Livingstone publishing. 2003.

20
6. Olumi AF, Richie JP. Urologic Surgery. In: Townsend CM, Beauchamp RD, Evers BM,
Mattox KL, editors. Sabiston’s Textbook of Surgery – the biological basis of modern surgical
practice. Elsevier-Saunders Publishing; 2004. p. 2283-2318.
7. Olumi AF, San Francisco I. Editorial letter: Matrix Metalloproteinases activity and stromal-
epithelial interactions. International Journal of Cancer. 2005:655.
8. Olumi AF, Editorial comment: The Vienna nomogram: validation of a novel biopsy strategy
defining the optimal number of cores based on patient age and total prostate volume. Journal
of Urology. 2005;174:1260-1.
9. Olumi AF, Editorial comment: Tumor necrosis as prognostic indicator in transitional cell
carcinoma of upper urinary tract. Journal of Urology. 2006;176:913-4.
10. Olumi AF. Editorial Comment. The impact factors on prognosis of pT3 patients with upper
urinary tract transitional cell carcinoma. Journal of Urology. 2007;178(2):450.
11. Olumi AF. Workforce Needed: Urology Physician-Scientists. American Urological
Association News. 2007;12(10):1.
12. Olumi AF, Richie JP. Urologic Surgery. In: Sabiston’s Textbook of Surgery – the biological
basis of modern surgical practice. Editors: Townsend CM, Beauchamp RD, Evers BM, Mattox
KL, editors. Philadelphia (PA): Elsevier; 2008. p. 2251-2286.
13. Wang Z, Ge R, Olumi AF, Apoptosis in Prostate Cancer. In: Apoptosis. Preedy, V, editor.
Enfield (NH): Science Publishers; 2010, p 293-309.
14. Olumi AF, Editorial Comment. Commentary on “Detecting DNA methylation of the BCL2,
CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain
reaction assay to predict bladder cancer. Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW,
Mydlo JH, Sidi AA, Adelson ME, Mordechai E, Trama JP. J Urol. 2012 Dec; 188(6):2101-7.”
Journal of Urology. 2012;188(6):2107.
15. Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL. Case records of the
Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass
in the bladder. New England Journal of Medicine. 2013;369(7):660-7.
16. Olumi AF, Editorial Comment, Commentary on "ETV1 directs androgen metabolism and
confers aggressive prostate cancer in targeted mice and patients." Baena E, Shao Z, Linn DE,
Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT,
Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z, Division of Hematology and Oncology,
Boston Children's Hospital, Boston, MA, USA.: Genes Dev 2013;27(6):683-98. Urologic
Oncology. 2014;32(2):213.
17. Olumi AF, Editorial Comment, Commentary on "age-related alterations in T-lymphocytes
modulate key pathways in prostate tumorigenesis." De Angulo A, Faris R, Cavazos D, Jolly C,
Daniel B, DeGraffenried L, Department of Nutritional Sciences, Dell Pediatric Research
Institute, University of Texas, Austin, TX, USA.: Prostate 2013;73(8):855-64 [Epub 2013 Mar
26]. Urologic Oncology. 2014;32(2):212-3
18. Olumi AF, Editorial Comment, Commentary on "integrative genomic analyses reveal an
androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J,
Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr
H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C,
Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S,
Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C,

21
Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk
D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L,
Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm
T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg,
Germany.: Cancer Cell 2013;23(2):159-70. Urologic Oncology. 2014;32:212
19. Olumi AF, Editorial Comment, Commentary on "identification of 23 new prostate cancer
susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch
S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J,
Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi
G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L,
Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G,
Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John
EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello
LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-
Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR,
Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K,
Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo
VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper
CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J,
Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD,
Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG,
Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi
DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G,
Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY,
Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou
AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of
GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer
Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK
ProtecT (Prostate testing for cancer and Treatment) Study. Urologic Oncology. 2014;32:211.
20. Olumi AF, Editorial Comment, Commentary on "the E3 ubiquitin ligase Siah2 contributes to
castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity."
Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW,
Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center,
Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell
2013;23(6):332-46. Urologic Oncology. 2014;32:210-1.
21. Olumi AF, Editorial Comment, Commentary on "randomized clinical trial of vitamin D3
doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients."
Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M,
Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R, Department of Nutritional
Sciences, University of Toronto, Ontario, Canada.: J Clin Endocrinol Metab 2013;98(4):1498-
507 [Epub 2013 Mar 5]. Urologic Oncology. 2014;32:210.
22. Olumi AF, Preston MA, Blute MS, Sr. Open Surgery of Kidney, In: Wein, AJ, Kavoussi LR,
Partin AW, Peters CA, editors. Campbell-Walsh Urology, 11th
edition, (In Press).

22
Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings:
Abstracts and exhibits presented at meetings during the last 3 years which have not already been
published as full length manuscripts
1. Ge R, Wang Z, Olumi AF. Metformin has an anti-cancer effect by repressing TWIST/N-
cadherin signaling. Poster Presentation, American Urological Association Annual Meeting,
2012, Atlanta, GA.
2. Siddiqui M, Paciorek A, Litwin MS, Olumi AF. Poor Follow-up and Low Socioeconomic
Status Predict Cancer-Specific Mortality in Men with Prostate Cancer. Poster Presentation,
American Urological Association Annual Meeting, 2012, Atlanta, GA.
3. Wirth G, Fendt SM, Bell E, Keibler M, Stephanopoulos G, Olumi AF. Metformin shifts
prostate cancer metabolism towards a less malignant phenotype. Podium Presentation,
American Urological Association Annual Meeting, 2012, Atlanta, GA.
4. Wang Z, Cheng Z, Cristofaro V, Gomez P, Sullivan M, Adam R, White M, Olumi AF.
Combination of Metformin and Inhibition of TNF-a reverse the bladder dysfunction associated
with type 2 diabetes. Podium Presentation, American Urological Association Annual Meeting,
2012, Atlanta, GA.
5. Rodríguez D, Olumi AF. Primary Spermatic Cord Tumors: Disease Characteristics,
Prognostic Factors And Treatment Outcomes. Podium Presentation, American Urological
Association Annual Meeting, 2012, Atlanta, GA.
6. Xiao X, Wang Z, Olumi AF. Metformin regulates the proliferation of prostate epithelial cells
inhibition of Insulin-like growth factor 1 receptor. Podium Presentation, American Urological
Association Annual Meeting, 2012, Atlanta, GA.
7. Ge R, Wang Z, Wu CL, Tabatabaei S, Olumi AF. Absence of 5-alpha Reductase 2 in Benign
Human Adult Prostates. Poster Presentation, American Urological Association Annual
Meeting, 2012, Atlanta, GA. (Winner of Best of AUA Award)
8. Wang Z, Cristofaro V, Cheng Z, Cao H, Ge R, Sullivan M, White M, Olumi AF. Correction of
hyperglycemia and hyperinsulinemia by genetic modification restores bladder dysfunction
associated with type 2 diabetes. Society of Basic Urologic Research Annual Meeting, 2013,
Nashville, TN.
9. Otsetov A, Ge R, Wang Z, Wu S, Wu CL, Tabatabaei S, Olumi AF. Higher Body Mass Index
is Associated with Methylation and Expression of 5-alpha reductase 2 in adult prostate tissues.
Society of Basic Urologic Research Annual Meeting, 2013, Nashville, TN. (Poster
Presentation Award Winner)
10. Ge R, Wang Z, Olumi AF. Metformin has an anti-cancer effect by repressing TWIST/N-
cadherin signaling. Society of Basic Urologic Research Annual Meeting, 2013, Nashville, TN.
(Podium Presentation Award Winner)
11. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF, Age
and Obesity Promote Methylation and Suppression of 5-Alpha Reductase 2-Implications for
Personalized Therapy in BPH. New England-American Urological Association Annual
Meeting, 2014, Newport, RI, (First Place Resident Essay Contest Winner)
12. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF, Age
and Obesity Promote Methylation and Suppression of 5-Alpha Reductase 2-Implications for
Personalized Therapy in BPH. American Urological Association Annual Meeting, 2015, New
Orleans, LO (Podium Presentation, Best Abstract Winner)

23
13. Wang Z, Cristofaro V, Cao H, Ge R, Sullivan M, Olumi AF. Enhanced ATP Release and
P2X1R Expression Contribute to Bladder Dysfunction in Type 2 Diabetes. Society of Basic
Urologic Research, 2015, Fort Lauderdale, FL (Selected for Podium Presentation)

24
Narrative Report
Introduction: As a urologist my clinical focus is urologic oncology and general urology. After
completing my residency at Brigham & Women’s Hospital (BWH) I joined the faculty at Beth Israel
Deaconess Medical Center and Harvard Medical School (HMS) as an Instructor in 2000. I was recruited
to Massachusetts General Hospital (MGH) as the Director of Urology Research in 2007 following a
national search. Throughout my career I have provided clinical care, supervised both clinical and basic
research trainees, administered a clinic, performed surgeries and conducted translational research.
Area of Excellence: My current translational research is primarily focused on the differential growth
pattern of the prostate gland in healthy adult men. Currently, I hold two active NIH grants. My NIH/R01
grant, which received 3rd
percentile score in its review process, is focused on regulation of 5-α reductase 2
gene, an important gene that is responsible for normal prostatic development and growth and a target of
commonly used 5-alpha reductase inhibitors (finasteride or dutasteride) for treating benign prostatic
hyperplasia (BPH). Generally believed to be ubiquitously expressed in all healthy adult men, we have
discovered that 30% of healthy adult men do not express the 5-α reductase 2 gene in their prostate,
accounting for millions of men who are inappropriately treated with 5-alpha reductase inhibitors each
year. I have shown that epigenetic factors such as DNA methylation affect expression of 5-α reductase 2
in human prostate tissue, thus suppressing the gene. My research has direct implications for developing
personalized care for management of BPH and prostate cancer chemoprevention (ref #9, “other peer
reviewed publications” section in CV). Currently, my active research grants total $1.36 million (direct
cost). My prior research grants, including 9 externally research funds, total $1.55 million (direct cost).
Throughout my career I have obtained $2.91 million (direct cost) research funding, thus far. One of my
early publications that described the chromosomal deletions in bladder cancer (ref #2) is the basis for a
widely used diagnostic test for patients with bladder cancer (UroVysion, Abbott Molecular Laboratories).
Recognizing my longstanding dedication to urologic research as a surgeon scientist, I have been selected
by the American Urological Association (AUA), the largest urologic professional society in the world
with 21,000 members, as the chairperson of AUA Research Program. In my new role, I will be
responsible for providing strategic oversight to the AUA Office of Research and develop and implement
new initiatives to facilitate the advancement of urologic research. I will oversee the activities of the AUA
research committees and will advocate for urologic research programs via direct interactions with NIH
and the US Congress.
Teaching: I have been actively involved in teaching and supervision of medical students, residents and
fellows since I joined the HMS faculty. I have developed a Urology core curriculum for the 2nd
year
medical students and act as the director of the Urology sessions in the HMS Renal Pathophysiology
course (course #: IN757.REN). In addition, annually, I lecture to the 2nd
year students in the Harvard
Science Technology (HST)-MIT program (course #: HT110).
After developing the first accredited urologic oncology fellowship program at MGH and serving as
the program director, I have successfully formed an alliance between MGH and BWH to create the first
Combined Harvard Urologic Oncology Fellowship program. I have developed a two-year curriculum for
urologic oncology fellows that draws expertise from MGH, BWH, Dana Farber Cancer Institute and
Harvard School of Public Health for teaching, learning and research opportunities.
Supportive Activity: I am the co-director of the Genitourinary Oncology Multidisciplinary Clinic, which
serves over 8,900 patients per year and has grown 6.6% in patient visits between 2010-2013. To enhance
their learning, annually, 15 fellows, 10 residents and 20 medical students rotate through this clinic. I
oversee, manage and ensure proper flow of patients, physicians (attendings, fellows and residents), nurses,
medical assistants and medical students. My clinical practice is focused on caring for patients with
urologic tumors, and I perform open, laparoscopic, robotic and endoscopic surgeries.

25
Summary: I began my academic career at Harvard as a urologic surgery resident in 1992 and rose to the
rank of Associate Professor in 2010. My time has been spent in clinical & surgical care, administrative
oversight of urologic research in our department, creation of the combined Harvard Urologic Oncology
Fellowship, teaching at HMS and MGH Residency and fellowship programs. I have an independent NIH
funded laboratory and have mentored 17 medical students, residents and fellows – 8 of whom now have
independent academic careers in clinical urology and basic research nationally and internationally. I
have been an invited lecturer nationally and participate in grant review processes and research
collaborative efforts internationally. My articles are frequently cited with nine of them cited over 100
times and one cited over 1000 times (ref #6). I serve on the editorial board of the most internationally
distributed journal in our field (Journal of Urology), and I am a selected national officer, Chair of
Research Council for the largest international urologic society, American Urological Association. In my
role as the Chair of Research for AUA, I play a leadership role in developing plans for research advocacy
at a national level with NIH and DOD, national conference planning, and enhancing research and
educational opportunities for the urologic research community.

Olumi_CV_4_2016

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Olumi_CV_4_2016

Similar to Olumi_CV_4_2016 (20)

Olumi_CV_4_2016